EMAIL THIS PAGE TO A FRIEND

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.


PMID 25838185

Abstract

The 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by the Ancillary Therapy and Supportive Care Working Group to support clinical research trials in chronic graft-versus-host disease (GVHD). Topics covered in that inaugural effort included the prevention and management of infections and common complications of chronic GVHD, as well as recommendations for patient education and appropriate follow-up. Given the new literature that has emerged during the past 8 years, we made further organ-specific refinements to these guidelines. Minimum frequencies are suggested for monitoring key parameters relevant to chronic GVHD during systemic immunosuppressive therapy and, thereafter, referral to existing late effects consensus guidelines is advised. Using the framework of the prior consensus, the 2014 NIH recommendations are organized by organ or other relevant systems and graded according to the strength and quality of supporting evidence.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

677469
Titanium(IV) oxide, contains 1% Mn as dopant, nanopowder, <100 nm particle size (BET), ≥97%
O2Ti
718467
Titanium(IV) oxide, nanopowder, 21 nm primary particle size (TEM), ≥99.5% trace metals basis
O2Ti
774510
Titanium(IV) oxide, nanowires, diam. × L ~100 nm × 10 μm
O2Ti
774529
Titanium(IV) oxide, nanowires, diam. × L ~10 nm × 10 μm
O2Ti
637254
Titanium(IV) oxide, anatase, nanopowder, <25 nm particle size, 99.7% trace metals basis
O2Ti
232033
Titanium(IV) oxide, anatase, powder, 99.8% trace metals basis
O2Ti
248576
Titanium(IV) oxide, anatase, powder, −325 mesh, ≥99% trace metals basis
O2Ti
634662
Titanium(IV) oxide, mixture of rutile and anatase, nanopowder, <100 nm particle size (BET), 99.5% trace metals basis
O2Ti
700355
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticle, <250 nm particle size (DLS), paste, 53-57 wt. % in diethylene glycol monobutyl ether/ethylene glycol, 99.9% trace metals basis
O2Ti
700347
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <150 nm particle size (volume distribution, DLS), dispersion, 40 wt. % in H2O, 99.5% trace metals basis
O2Ti
700339
Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <100 nm particle size, dispersion, 48-52 wt. % in xylene, 99.9% trace metals basis
O2Ti
204730
Titanium(IV) oxide, rutile, 99.995% trace metals basis
O2Ti
204757
Titanium(IV) oxide, rutile, ≥99.98% trace metals basis
O2Ti
635057
Titanium(IV) oxide, rutile, <001>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
635049
Titanium(IV) oxide, rutile, <100>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
635065
Titanium(IV) oxide, rutile, <110>, single crystal substrate, ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm
O2Ti
637262
Titanium(IV) oxide, rutile, nanopowder, <100 nm particle size, 99.5% trace metals basis
O2Ti
224227
Titanium(IV) oxide, rutile, powder, <5 μm, ≥99.9% trace metals basis
O2Ti